loading
Schlusskurs vom Vortag:
$4.64
Offen:
$4.6
24-Stunden-Volumen:
14,526
Relative Volume:
0.36
Marktkapitalisierung:
$41.07B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-6.3452
EPS:
-0.7092
Netto-Cashflow:
-
1W Leistung:
+5.88%
1M Leistung:
+29.68%
6M Leistung:
+219.15%
1J Leistung:
+139.35%
1-Tages-Spanne:
Value
$4.423
$4.60
1-Wochen-Bereich:
Value
$4.19
$4.69
52-Wochen-Spanne:
Value
$1.001
$5.87

Alterity Therapeutics Ltd Adr Stock (ATHE) Company Profile

Name
Firmenname
Alterity Therapeutics Ltd Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
10
Name
Twitter
@AlterityT
Name
Nächster Verdiensttermin
2024-08-29
Name
Neueste SEC-Einreichungen
Name
ATHE's Discussions on Twitter

Vergleichen Sie ATHE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATHE
Alterity Therapeutics Ltd Adr
4.50 62.91M 0 0 0 0.00
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Alterity Therapeutics Ltd Adr Stock (ATHE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-03 Herabstufung The Benchmark Company Speculative Buy → Hold
2024-12-12 Eingeleitet Maxim Group Buy

Alterity Therapeutics Ltd Adr Aktie (ATHE) Neueste Nachrichten

pulisher
May 12, 2025

Alterity Therapeutics highlighted at MSA Congress - Investing.com

May 12, 2025
pulisher
May 12, 2025

Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India

May 12, 2025
pulisher
May 07, 2025

Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com

May 07, 2025
pulisher
May 07, 2025

Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
Apr 10, 2025

Alterity shares new phase 2 data on MSA treatment - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Alterity shares new phase 2 data on MSA treatment By Investing.com - Investing.com India

Apr 10, 2025
pulisher
Apr 07, 2025

Alterity Therapeutics announces regulatory notice - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Alterity Therapeutics completes placement - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK

Apr 07, 2025
pulisher
Apr 07, 2025

Alterity Therapeutics completes placement By Investing.com - Investing.com UK

Apr 07, 2025
pulisher
Mar 27, 2025

ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Alterity Concludes Open-Label Trial Patient Visits - Investing.com

Mar 27, 2025
pulisher
Feb 18, 2025

Alterity Therapeutics announces compliance notice - Investing.com

Feb 18, 2025
pulisher
Feb 18, 2025

Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks

Feb 18, 2025
pulisher
Feb 13, 2025

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.

Feb 13, 2025
pulisher
Feb 10, 2025

Alterity Therapeutics raises A$40M in placement - TipRanks

Feb 10, 2025
pulisher
Feb 10, 2025

Alterity secures funding to advance MSA drug development - Investing.com India

Feb 10, 2025
pulisher
Feb 06, 2025

JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks

Feb 06, 2025
pulisher
Feb 06, 2025

Alterity Therapeutics announces trading halt - Investing.com

Feb 06, 2025
pulisher
Feb 05, 2025

Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks

Feb 05, 2025
pulisher
Feb 05, 2025

JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks

Feb 05, 2025
pulisher
Feb 05, 2025

Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa

Feb 05, 2025
pulisher
Feb 05, 2025

Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com

Feb 05, 2025
pulisher
Feb 04, 2025

Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks

Feb 04, 2025
pulisher
Feb 04, 2025

Alterity Therapeutics announces securities notice - Investing.com

Feb 04, 2025
pulisher
Feb 03, 2025

Alterity Therapeutics Completes Significant Share Issuance - TipRanks

Feb 03, 2025
pulisher
Feb 03, 2025

Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks

Feb 03, 2025
pulisher
Feb 03, 2025

Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN

Feb 03, 2025
pulisher
Feb 02, 2025

Alterity Therapeutics Announces Major Securities Placement - TipRanks

Feb 02, 2025
pulisher
Feb 02, 2025

Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks

Feb 02, 2025
pulisher
Jan 29, 2025

Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks

Jan 29, 2025
pulisher
Jan 27, 2025

Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks

Jan 27, 2025
pulisher
Jan 25, 2025

Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register

Jan 25, 2025
pulisher
Jan 24, 2025

Alterity Therapeutics reports quarterly activities - Investing.com

Jan 24, 2025
pulisher
Jan 24, 2025

Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK

Jan 24, 2025
pulisher
Jan 23, 2025

Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks

Jan 23, 2025
pulisher
Jan 22, 2025

Alterity Therapeutics Expands ASX Quoted Securities - TipRanks

Jan 22, 2025
pulisher
Jan 21, 2025

Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks

Jan 21, 2025
pulisher
Jan 16, 2025

Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks

Jan 16, 2025
pulisher
Jan 07, 2025

Opthea reports positive Phase 1b DME trial results - Investing.com

Jan 07, 2025
pulisher
Dec 31, 2024

ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead

Dec 31, 2024
pulisher
Dec 04, 2024

ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead

Dec 04, 2024
pulisher
Nov 22, 2024

Alterity Therapeutics reports annual general meeting results - Investing.com

Nov 22, 2024
pulisher
Nov 19, 2024

Alterity Therapeutics announces change in company secretary - Investing.com

Nov 19, 2024
pulisher
Nov 15, 2024

Opthea adds Kathy Connell to Board of Directors - Investing.com

Nov 15, 2024
pulisher
Oct 15, 2024

Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com

Oct 15, 2024
pulisher
Feb 15, 2024

Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead

Feb 15, 2024
pulisher
Aug 17, 2023

Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead

Aug 17, 2023
pulisher
Jan 06, 2023

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire

Jan 06, 2023
pulisher
Jul 28, 2018

ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content

Jul 28, 2018

Finanzdaten der Alterity Therapeutics Ltd Adr-Aktie (ATHE)

Es liegen keine Finanzdaten für Alterity Therapeutics Ltd Adr (ATHE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$304.56
price up icon 3.98%
$573.26
price down icon 1.32%
$30.14
price down icon 3.74%
$490.28
price down icon 19.01%
$1.08
price up icon 1.89%
Kapitalisierung:     |  Volumen (24h):